tirzepatide surpass 2 versus Semaglutide in Type Diabetes (SURPASS-2) | NEJM | Med Journal Club Tirzepatide's effects on body weight

The neuroprotective effects of GLP-1R agonists may be closely related to their impact on insulin resistance and glucose metabolism

Cardiovascular outcome trials have demonstrated significant reductions in major adverse cardiovascular events with certain agents in this class (liraglutide, injectable semaglutide, and dulaglutide), leading to expanded indications for cardiovascular risk reduction

The landmark SURMOUNT-1 trial demonstrated that participants receiving the highest dose of tirzepatide lost up to 22.5% of their total body weight over 72 weeks

Problems With Sourcing And Unauthorized Forms When a pharmacy compounds an active ingredient, federal regulations require it to obtain the active ingredient from an FDA-registered supplier

Red flags requiring immediate evaluation include severe abdominal pain (possible pancreatitis), persistent vomiting leading to dehydration, suicidal thoughts, development of new eating disorder behaviors, syncope, chest pain, hematemesis/melena, severe constipation/obstipation, orthostatic hypotension, or marked electrolyte abnormalities

Table of Contents Understanding How Wegovy Works in Your Body Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities